-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CYP-001 in Graft Versus Host Disease (GVHD)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CYP-001 in Graft Versus Host Disease (GVHD) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CYP-001 in Graft Versus Host Disease (GVHD) Drug Details:...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – LP-410 in Graft Versus Host Disease (GVHD)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - LP-410 in Graft Versus Host Disease (GVHD) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. LP-410 in Graft Versus Host Disease (GVHD) Drug Details:...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CS-12192 in Graft Versus Host Disease (GVHD)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CS-12192 in Graft Versus Host Disease (GVHD) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CS-12192 in Graft Versus Host Disease (GVHD) Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Acalabrutinib Maleate in Graft Versus Host Disease (GVHD)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Acalabrutinib Maleate in Graft Versus Host Disease (GVHD) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Acalabrutinib Maleate in Graft Versus Host Disease...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Ivarmacitinib Sulfate in Graft Versus Host Disease (GVHD)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ivarmacitinib Sulfate in Graft Versus Host Disease (GVHD) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ivarmacitinib Sulfate in Graft Versus Host Disease...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – TDI-01 in Graft Versus Host Disease (GVHD)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - TDI-01 in Graft Versus Host Disease (GVHD) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. TDI-01 in Graft Versus Host Disease (GVHD) Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Brentuximab Vedotin in Graft Versus Host Disease (GVHD)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Brentuximab Vedotin in Graft Versus Host Disease (GVHD) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Brentuximab Vedotin in Graft Versus Host Disease (GVHD)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – TRGFT-201 in Graft Versus Host Disease (GVHD)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - TRGFT-201 in Graft Versus Host Disease (GVHD) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. TRGFT-201 in Graft Versus Host Disease (GVHD) Drug...
-
Product Insights
Corneal Graft Rejection – Drugs In Development, 2023
Global Markets Direct’s, ‘Corneal Graft Rejection - Drugs In Development, 2023’, provides an overview of the Corneal Graft Rejection pipeline landscape. The report provides comprehensive information on the therapeutics under development for Corneal Graft Rejection, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Delayed Graft Function (DGF) – Drugs In Development, 2023
Global Markets Direct’s, ‘Delayed Graft Function (DGF) - Drugs In Development, 2023’, provides an overview of the Delayed Graft Function (DGF) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Delayed Graft Function (DGF), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...